Indication
Esophageal Squamous Cell Carcinoma
50 clinical trials
60 products
17 drugs
Product
pembrolizumabClinical trial
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal CancerStatus: Active (not recruiting), Estimated PCD: 2023-07-26
Product
THOR-707Product
PembrolizumabProduct
CetuximabProduct
SGN-PDL1VClinical trial
A Phase 1 Study of SGN-PDL1V in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-31
Product
TislelizumabClinical trial
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2020-12-01
Product
DocetaxelProduct
PaclitaxelProduct
IrinotecanClinical trial
A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesStatus: Terminated, Estimated PCD: 2024-01-15
Product
TNO155Product
SpartalizumabProduct
RibociclibProduct
LomvastomigClinical trial
An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A.Status: Recruiting, Estimated PCD: 2024-11-08
Product
Favezelimab + PembrolizumabProduct
MK-4830Product
LenvatinibClinical trial
Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-04-01
Product
SI-B001Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-02-28
Product
OxaliplatinProduct
CapecitabineProduct
PlaceboProduct
CisplatinProduct
FluorouracilClinical trial
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2025-02-13
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)Status: Active (not recruiting), Estimated PCD: 2027-02-01
Product
levoleucovorinProduct
oxaliplatinProduct
placeboProduct
cisplatinProduct
5-FUProduct
leucovorinClinical trial
A Phase 2, Multicenter, Open-label, 2-Cohort Study to Investigate the Efficacy and Safety of PET Guided Neoadjuvant Treatment With Tislelizumab (BGB-A317) Plus Chemotherapy/Chemoradiotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-04-17
Clinical trial
Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Product
PenpulimabProduct
TQB2618Product
AP203Clinical trial
A Phase 1/2, Open-label Study of the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected MalignanciesStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 in Combination With Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
LBL-007Product
ChemotherapyClinical trial
Phase II Clinical Study of Adebrelimab Combined With Apatinib and Tegafur in the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Failed First-line Immunotherapy Combined With ChemotherapyStatus: Recruiting, Estimated PCD: 2026-03-01
Drug
AdebrelimabProduct
ApatinibProduct
TegafurClinical trial
Postoperative Adjuvant Immune Maintenance Therapy for High Recurrence Risk Esophageal Squamous Cell Carcinoma After Radical Resection: a Multicenter Randomized Controlled Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Drug
sintilimabClinical trial
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Drug
AdavosertibClinical trial
Phase III Multicenter Randomized Controlled Trial of PD-1 Inhibitor Combined With Preoperative Concurrent Chemoradiotherapy and Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (NEOCRTEC2101)Status: Recruiting, Estimated PCD: 2031-01-01
Product
SintilimabDrug
CisplatinClinical trial
A Phase Ib/II Trial of Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-05-31
Drug
TiragolumabClinical trial
Efficacy and Safety of Concurrent Sintilimab and Radiotherapy With Immunonutrition Support in Esophageal Cancer: A Phase II Multicenter Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER TrialStatus: Active (not recruiting), Estimated PCD: 2023-02-01
Product
NivolumabClinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-07
Product
XB002Drug
fluorouracilProduct
DTXDrug
T-VECClinical trial
Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
Role of Local Therapy for Patients With Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma After Radical Treatment: a Prospective, Randomized Phase II Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2022-01-01
Product
Systemic therapyClinical trial
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal CancerStatus: Recruiting, Estimated PCD: 2026-12-21
Drug
AN0025Drug
DocetaxelClinical trial
Prospective, Single-arm Phase II Exploratory Study of the Efficacy and Safety of IBI110 Combined With Sintilimab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Has Failed First-line Anti-PD-1 Antibody TherapyStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Product
IBI110+SintilimabClinical trial
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal EffectStatus: Completed, Estimated PCD: 2022-01-20
Clinical trial
A Prospective, Randomized Controlled Clinical Trial of Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2029-05-01
Drug
AnlotinibProduct
FOLFOXClinical trial
A Phase III, Randomized, Multicenter Study of PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-02-17
Product
PD-1 InhibitorsDrug
IrinotecanClinical trial
Real-world Experience of Immunotherapy Plus Chemotherapy as First-line Treatment With or Without Radiotherapy for Patients With Advanced Oesophageal Squamous Cell Carcinoma in ChinaStatus: Completed, Estimated PCD: 2023-12-04
Product
Chemotherapy + ImmunotherapyProduct
CAPOXDrug
5-FUClinical trial
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma：A Single Arm, Single Center, Prospective Clinical Trial (POINTS Trial)Status: Not yet recruiting, Estimated PCD: 2025-04-20
Clinical trial
First-line Anti-PD-1 Therapy Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Multi-center, Randomized Trial (SCR-ESCC-01)Status: Recruiting, Estimated PCD: 2026-01-01
Drug
PD-1 antibodyClinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified CutoffStatus: Recruiting, Estimated PCD: 2025-09-30
Drug
SpartalizumabClinical trial
The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction CancerStatus: Active (not recruiting), Estimated PCD: 2014-07-15
Product
CixutumumabClinical trial
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
CDK4/6 Inhibitor Palbociclib Combined With Afatinib as Second-line Treatment for Advanced Squamous Carcinoma of the Esophagus or Gastroesophageal Junction Progressed on at Least First-line Chemotherapy: a Phase 2 TrialStatus: Recruiting, Estimated PCD: 2025-04-01
Product
PalbociclibProduct
AfatinibClinical trial
A Multicenter, Open-label, Randomized, Controlled Phase II Study to Evaluate the Efficacy and Safety of Afatinib Versus Irinotecan as a Second-line and Above Treatment for Advanced ALTRK-negative ESCCStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Toripalimab After Radiotherapy Alone in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2024-04-30
Clinical trial
Systemic Therapy Combined With Thoracic Concurrent Chemoradiotherapy Versus Systemic Therapy Alone in Stage IVB Esophageal Squamous Cell Carcinoma: A Prospective Randomized Phase II StudyStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Neoadjuvant Tislelizumab Combined With Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma : Single Arm Phase II StudyStatus: Recruiting, Estimated PCD: 2023-10-20
Clinical trial
Efficacy and Safety of Toripalimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Phase II Trial (EC-CRT-007)Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Single-arm, Multicenter, Exploratory Study of Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Product
cadonilimab+chemotherapyClinical trial
Safety and Efficacy of Cadonilimab Combined With Anlotinib in Neoadjuvant Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: a Single Arm, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Product
Cadonilimab + AnlotinibClinical trial
Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal CancerStatus: Active (not recruiting), Estimated PCD: 2022-09-13
Product
Capecitabine(Aibin)Product
Oxaliplatin(Aiheng)Clinical trial
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Clinical TrialStatus: Recruiting, Estimated PCD: 2025-04-01
Product
SerplulimabClinical trial
Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)Status: Recruiting, Estimated PCD: 2025-07-31
Drug
tislelizumabClinical trial
The Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable Esophageal Squamous Cell CarcinomaStatus: , Estimated PCD: 2024-06-20
Clinical trial
Ivonescimab(AK112) Combined With Chemotherapy as the First-line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single Arm , Phase II TrialStatus: Not yet recruiting, Estimated PCD: 2024-08-30
Product
IvonescimabClinical trial
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study): a Single-arm, Phase II StudyStatus: Completed, Estimated PCD: 2023-07-24
Product
BI-754091 plus Afatinib